These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6433121)

  • 1. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services.
    Nelson AA; Reeder CE; Dickson WM
    Med Care; 1984 Aug; 22(8):724-36. PubMed ID: 6433121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differential impact of copayment on drug use in a Medicaid population.
    Reeder CE; Nelson AA
    Inquiry; 1985; 22(4):396-403. PubMed ID: 2934334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copayment for pharmaceutical services in a Medicaid program.
    Nelson AA; Quick MR
    Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Health Outcomes and Prescription Drug Copayments in Medicaid.
    Kostova D; Fox J
    Med Care; 2017 May; 55(5):520-527. PubMed ID: 28234755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids.
    Meissner BL; Moore WM; Shinogle JA; Reeder CE; Little JM
    J Manag Care Pharm; 2004; 10(3):226-33. PubMed ID: 15228372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who bears the burden of Medicaid drug copayment policies?
    Stuart B; Zacker C
    Health Aff (Millwood); 1999; 18(2):201-12. PubMed ID: 10091449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing prescribing patterns and increasing prescription expenditures in Medicaid.
    Fink KS; Byrns PJ
    Ann Fam Med; 2004; 2(5):488-93. PubMed ID: 15506586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.
    Soumerai SB; Avorn J; Ross-Degnan D; Gortmaker S
    N Engl J Med; 1987 Aug; 317(9):550-6. PubMed ID: 3302713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Medicaid drug expenditures.
    Sudovar SG; Rein SD
    J Health Hum Resour Adm; 1978 Nov; 1(2):200-30. PubMed ID: 10308767
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.
    Domino ME; Martin BC; Wiley-Exley E; Richards S; Henson A; Carey TS; Sleath B
    Health Serv Res; 2011 Jun; 46(3):900-19. PubMed ID: 21306363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population.
    Bae SJ; Paltiel AD; Fuhlbrigge AL; Weiss ST; Kuntz KM
    Value Health; 2008; 11(1):110-8. PubMed ID: 18237365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicaid prescription drug utilization and expenditures following Part D.
    Farley JF; Dusetzina SB
    J Health Care Poor Underserved; 2010 May; 21(2):715-28. PubMed ID: 20453368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.
    Lurk JT; DeJong DJ; Woods TM; Knell ME; Carroll CA
    Am J Health Syst Pharm; 2004 Feb; 61(3):267-72. PubMed ID: 14986557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.